[go: up one dir, main page]

AU2001279775A1 - Medicament for the immunotherapy of malignant tumours - Google Patents

Medicament for the immunotherapy of malignant tumours

Info

Publication number
AU2001279775A1
AU2001279775A1 AU2001279775A AU7977501A AU2001279775A1 AU 2001279775 A1 AU2001279775 A1 AU 2001279775A1 AU 2001279775 A AU2001279775 A AU 2001279775A AU 7977501 A AU7977501 A AU 7977501A AU 2001279775 A1 AU2001279775 A1 AU 2001279775A1
Authority
AU
Australia
Prior art keywords
medicament
immunotherapy
malignant tumours
tumors
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001279775A
Inventor
Armin Grossmann
Klaus-Dieter Rockensuss
Claudia Ulbrich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LipoNova AG
Original Assignee
LipoNova AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LipoNova AG filed Critical LipoNova AG
Publication of AU2001279775A1 publication Critical patent/AU2001279775A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to a composition which can be used as a medicament or for preparing a medicament for the immunotherapy of tumors of for tumor vaccination. The invention also relates to methods for preparing medicaments for the immuno-therapy of tumors of for tumor vaccination.
AU2001279775A 2000-07-28 2001-07-21 Medicament for the immunotherapy of malignant tumours Abandoned AU2001279775A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00116362 2000-07-28
EP00116362 2000-07-28
PCT/EP2001/008455 WO2002009745A1 (en) 2000-07-28 2001-07-21 Medicament for the immunotherapy of malignant tumours

Publications (1)

Publication Number Publication Date
AU2001279775A1 true AU2001279775A1 (en) 2002-02-13

Family

ID=8169380

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001279775A Abandoned AU2001279775A1 (en) 2000-07-28 2001-07-21 Medicament for the immunotherapy of malignant tumours

Country Status (19)

Country Link
US (2) US20030129206A1 (en)
EP (1) EP1305041B1 (en)
JP (1) JP2004505058A (en)
AT (1) ATE330626T1 (en)
AU (1) AU2001279775A1 (en)
BG (1) BG107482A (en)
CA (1) CA2417374A1 (en)
CY (1) CY1105179T1 (en)
CZ (1) CZ299669B6 (en)
DE (1) DE50110274D1 (en)
DK (1) DK1305041T3 (en)
ES (1) ES2267800T3 (en)
HU (1) HUP0300772A3 (en)
NO (1) NO20030420L (en)
PL (1) PL358675A1 (en)
PT (1) PT1305041E (en)
SI (1) SI1305041T1 (en)
SK (1) SK822003A3 (en)
WO (1) WO2002009745A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211971A1 (en) * 2001-09-17 2003-11-13 Srivastava Pramod K. Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
CN1764375A (en) * 2003-02-20 2006-04-26 康涅狄格大学健康中心 Methods for using compositions comprising heat shock proteins or alpha-2-macroglobulin in the treatment of cancer and infectious disease
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
MY160857A (en) 2006-02-03 2017-03-31 Malaysian Palm Oil Board A cancer vaccine
EP1974742A1 (en) * 2007-03-29 2008-10-01 LipoNova AG A method for improving the manufacturing process of a tumour vaccine
CN102470167A (en) 2009-07-02 2012-05-23 Ith免疫治疗控股公司 Exosome-Based Cancer Therapy
CN105807053B (en) 2016-04-15 2019-04-02 苏州药明康德新药开发股份有限公司 A kind of application of the tumour dissociation reagent in FCM analysis
EP3425400B1 (en) 2017-07-05 2022-01-26 VCC Medical Deutschland GmbH Method for manufacturing a tumor vaccine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
DE19633731A1 (en) * 1996-08-21 1998-02-26 Johann Hinrich Prof Dr Peters Hybrid cells used as anti-cancer vaccine
WO1999042564A2 (en) * 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
DE19812004A1 (en) * 1998-03-19 1999-09-30 Forschungszentrum Juelich Gmbh Dehydrogenases with improved NAD dependence, their production and use
AU3102799A (en) * 1998-03-20 1999-10-11 Genzyme Corporation Enhanced anti-tumor immunity
EP1076564B1 (en) * 1998-04-02 2008-10-29 The Regents of the University of California Compositions for enhancing antigen-presenting cells and anti-tumor responses in a human patient
US6045990A (en) * 1998-07-09 2000-04-04 Baust; John M. Inclusion of apoptotic regulators in solutions for cell storage at low temperature

Also Published As

Publication number Publication date
ATE330626T1 (en) 2006-07-15
NO20030420D0 (en) 2003-01-27
NO20030420L (en) 2003-01-27
SK822003A3 (en) 2004-05-04
JP2004505058A (en) 2004-02-19
HUP0300772A2 (en) 2003-08-28
HK1055562A1 (en) 2004-01-16
CA2417374A1 (en) 2003-01-27
EP1305041B1 (en) 2006-06-21
DE50110274D1 (en) 2006-08-03
US20070134275A1 (en) 2007-06-14
DK1305041T3 (en) 2006-10-23
HUP0300772A3 (en) 2005-11-28
WO2002009745A1 (en) 2002-02-07
PL358675A1 (en) 2004-08-09
BG107482A (en) 2003-11-28
US20030129206A1 (en) 2003-07-10
ES2267800T3 (en) 2007-03-16
CY1105179T1 (en) 2010-03-03
PT1305041E (en) 2006-09-29
CZ299669B6 (en) 2008-10-08
EP1305041A1 (en) 2003-05-02
SI1305041T1 (en) 2006-12-31
CZ2003179A3 (en) 2004-01-14

Similar Documents

Publication Publication Date Title
YU23202A (en) Drugs for the treatment of malignant tumors
IL148782A0 (en) Drugs for the treatment of malignant tumours
EP1468014A4 (en) Compositions and methods for wt1 specific immunotherapy
AU2001233726A1 (en) Farnesyl protein transferase inhibitors for treating breast cancer
AU9660801A (en) Compositions and methods for wt1 specific immunotherapy
SE9901875D0 (en) Novel compounds
MXPA03007837A (en) Compositions for delivering bisphosphonates.
TW200509967A (en) Compositions and methods for WT1 specific immunotherapy
MY128924A (en) Novel compounds
IL146125A0 (en) Novel quinones as disease therapies
WO2001025273A3 (en) Compositions and methods for wt1 specific immunotherapy
AU2001279775A1 (en) Medicament for the immunotherapy of malignant tumours
WO2001035989A3 (en) Use of anti-idiotypical antibodies as vaccines against cancer
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
TW200504051A (en) Novel acridine derivatives and their use as medicaments
ZA200106725B (en) Use of an enterobacterium protein ompa associated with an antigen for generating an antiviral antiparasitic or antitumoral cytotoxic response.
MXPA03005374A (en) Antitumoral carbazoles.
MX2010004332A (en) Hydrated crystalline esters of camptothecin for the treatment of cancer.
AU2001256440A1 (en) Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent
AU2002352011A1 (en) Immunogenic alk (anaplastic lymphoma kinase) peptides
UA87292C2 (en) Use of siramesin for treatment of malignant tumors
WO2003035104A3 (en) Compositions and methods for selected tumor treatment
MXPA05006378A (en) Steroid compounds with anti-tumor activity.
UA49216A (en) Remedy for treating complication following resection of malignant tumors of skin
DE60235085D1 (en) PREPARATION OF DERIVATIVES OF BISPHOSPHONATES